<DOC>
	<DOCNO>NCT00544609</DOCNO>
	<brief_summary>Safety profile determine maximum tolerate dose Sorafenib combination Radiotherapy Treatment Invasive Bladder Cancer With Conservative Intent</brief_summary>
	<brief_title>Sorafenib Radiotherapy Treatment Invasive Bladder Cancer With Conservative Intent</brief_title>
	<detailed_description>Study phase I patient Invasive Bladder Cancer</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients diagnose urothelial carcinoma bladder , clinical stage T24a N0 M0 ( multifocal evaluation lesion biopsy ) , candidate radical cystectomy medical reason refusal . No prior treatment radiotherapy bladder systemic chemotherapy . Patients must ≥ 18 year old . Patients must ECOG performance status 0 2 . Life expectancy least 12 week . Patients adequate bone marrow , hepatic renal function assess follow laboratory requirement conduct within 7 day prior screen : hemoglobin ≥ 9.0 g/dl absolute neutrophil count ≥ 1.500/mm3 platelet ≥ 100.000/mm3 . total bilirubin ≤ 1.5 time upper limit normality SGOT ( AST ) and/or SGPT ( ALT ) ≤ 2.5 time upper limit normality alkaline phosphatase ≤ 4 x ULN serum creatinine ≤1.5 upper limit normality PTINR/PTT &lt; 1.5 x upper limit normality creatinine clearance ≥ 40 ml/min use CockcroftGaul Patients must give write informed consent procedure relate study perform ; therefore , must give selection visit . The patient must inform right withdraw study time , without kind prejudice . Patients capable accomplish study 's requirement without impediment follow instruction . Women fertile age must negative result pregnancy test perform 7 day begin administration study medication . Patients sex must use adequate contraceptive method ( oral injectable contraceptive , intrauterine device , condom , sterilization ) whilst participate protocol . After retreat treatment sorafenib , contraceptive method must use 4 week woman 3 month men . Patients active infection serious medical condition ( autologous bone marrow transplant stem cell rescue within 4 month study , patient undergoing renal dialysis , know HIV infection chronic hepatitis B C , active clinically serious infection &gt; CTCAE Grade 2 , nonhealing wound , ulcer , bone fracture ) . Abuse substance , clinical condition , psychological social , would preclude appropriate inform consent compliance protocol . Concurrent treatment experimental drug ( within 30 day prior study entry ) . Concurrent treatment anticancer immunotherapy study within 4 week study entry . Treatment wuth mitomycin C nitrosureas 6 week prior study entry . History prior malignancy within precede 5 year previously treat basal cell carcinoma skin , incipient prostate cancer situ cervix carcinoma . Pregnant breast feeding patient . Known suspect allergy sorafenib . Cardiac disease : Congestive heart failure &gt; class II NYHA ; active CAD ( myocardial infarction 6 month study entry allow ) ; cardiac arrythmias require antiarrythmic therapy ( beta blocker digoxin permit ) . Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management . Known brain metastasis . Patients neurological symptom undergo CT scan/MRI brain exclude brain metastasis . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Patients hydronephrosis . Patients seizure disorder require medication ( steroids antiepileptic ) . History organ allograft . Patient unable swallow oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Bladder</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>